Skip to contentS
Starling Oncology, Inc.
S
STLNStarling Oncology, Inc. Q2 2023 · 10-Q
Revenue$80.22M$80.22M+31.7% vs Q2 2022 Net Income-$16.90M-$16.90MN/M vs Q2 2022 EPS Diluted-$0.19-$0.19N/M vs Q2 2022 Operating Income-$14,938,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,597,000N/M Margins · derivedOperating margin-18.6%+11.4 pt vs Q2 2022
Net margin-21.1%−12.1 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 9, 2023 · 40 d after period end